Literature DB >> 15311551

Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer.

H Dülger1, S Alici, M R Sekeroğlu, R Erkog, H Ozbek, T Noyan, M Yavuz.   

Abstract

The aim was to investigate the serum levels of leptin, TNF-alpha, IL-1 beta, IL-6, insulin, and growth hormone in patients with upper gastrointestinal cancer and cachexia. A total of 39 patients with various advanced stage (stage IV) gastrointestinal malignancies were enrolled. These cancer patients were divided into two groups according to the presence or absence of cachexia. Fifteen healthy adults were recruited as the control group. Body mass index (BMI; kg/m2) was calculated. Serum leptin, tumour necrosis factor (TNF)-alpha interleukin (IL)-1 beta, interleukin (IL)-6, growth hormone, insulin, glucose, triglyceride, total protein, albumin, erythrocyte sedimentation rate, and CRP were measured. In both cancer groups (cachectic and non-cachectic) body mass index and serum leptin levels were lower than controls (p < 0.001). Serum IL-1 beta, IL-6, and growth hormone levels were higher in both cachectic and non-cachectic groups than those of controls (p < 0.05). Serum TNF-alpha level in non-cachectic group was also significantly higher than in control group (p < 0.01). There is no significant difference between three groups in terms of insulin resistance as assessed by HOMA index. Our results showed that some proinflammatory cytokine levels were increased and leptin level was decreased due to upper gastrointestinal cancers. Increased cytokine levels may lead to decreased food intake and caused a weight loss.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15311551     DOI: 10.1111/j.1368-5031.2004.00149.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  17 in total

1.  Serum protein markers for early detection of ovarian cancer.

Authors:  Gil Mor; Irene Visintin; Yinglei Lai; Hongyu Zhao; Peter Schwartz; Thomas Rutherford; Luo Yue; Patricia Bray-Ward; David C Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-12       Impact factor: 11.205

Review 2.  Cancer- and cardiac-induced cachexia: same fate through different inflammatory mediators?

Authors:  Rita Nogueira-Ferreira; Fábio Sousa-Nunes; Adelino Leite-Moreira; Liliana Moreira-Costa; Rui Vitorino; Lúcio Lara Santos; Daniel Moreira-Gonçalves; Rita Ferreira
Journal:  Inflamm Res       Date:  2022-06-09       Impact factor: 6.986

3.  The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer.

Authors:  Ozgur Kemik; Aziz Sumer; Ahu Sarbay Kemik; Ismail Hasirci; Sevim Purisa; Ahmet Cumhur Dulger; Baris Demiriz; Sefa Tuzun
Journal:  World J Surg Oncol       Date:  2010-09-28       Impact factor: 2.754

4.  Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers.

Authors:  Anne E Utech; Eiriny M Tadros; Teresa G Hayes; Jose M Garcia
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-05-31       Impact factor: 12.910

5.  Connexin 43 mediated gap junctional communication enhances breast tumor cell diapedesis in culture.

Authors:  Mary-Ann Pollmann; Qing Shao; Dale W Laird; Martin Sandig
Journal:  Breast Cancer Res       Date:  2005-05-13       Impact factor: 6.466

6.  Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer.

Authors:  Yutaka Fujiwara; Takashi Kobayashi; Naoko Chayahara; Yoshinori Imamura; Masanori Toyoda; Naomi Kiyota; Toru Mukohara; Shin Nishiumi; Takeshi Azuma; Masaru Yoshida; Hironobu Minami
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

7.  Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle.

Authors:  Theodore P Braun; Marek Szumowski; Peter R Levasseur; Aaron J Grossberg; XinXia Zhu; Anupriya Agarwal; Daniel L Marks
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

8.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07

9.  CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype.

Authors:  N A Helsby; W-Y Lo; K Sharples; G Riley; M Murray; K Spells; M Dzhelai; A Simpson; M Findlay
Journal:  Br J Cancer       Date:  2008-10-21       Impact factor: 7.640

10.  An extensive phenotypic characterization of the hTNFalpha transgenic mice.

Authors:  Michael D Hayward; Beverly K Jones; Arman Saparov; Heather S Hain; Anne-Cecile Trillat; Michelle M Bunzel; Aaron Corona; Bifang Li-Wang; Bryan Strenkowski; Caroline Giordano; Hai Shen; Emily Arcamone; Jeffrey Weidlick; Maria Vilensky; Marina Tugusheva; Roland H Felkner; William Campbell; Yu Rao; David S Grass; Olesia Buiakova
Journal:  BMC Physiol       Date:  2007-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.